Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03686384 · ClinicalTrials.gov registry record · Phase 3
SVT-15652 Otic Solution for the Treatment of Otomycosis
A Phase 3 study, sponsored by Salvat.
- Completed
- Registry status
- Phase 3
- Development phase
- 217
- Enrollment target
NCT03686384 is a Phase 3 study that has completed, run by Salvat. The registered enrollment target is 217 participants.
The verdict
NCT03686384, a Phase 3 study, has completed, sponsored by Salvat.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 217 participants
- Enrollment target
Study Summary
Multicenter, randomized, 2-arm parallel-group, double blind, placebo-controlled study in patients suffering from Otomycosis. This study will compare the efficacy and safety of SVT-15652 otic solution to that of Placebo, when administering one vial twice daily during 14 days.
Interventions
- DRUG Placebo
- DRUG SVT-15652
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2020-02-27 |
| Est. Completion | 2021-10-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03686384
The ClinicalTrials.gov registry entry for NCT03686384 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Salvat, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03686384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03686384 about?
NCT03686384 is a clinical study titled "SVT-15652 Otic Solution for the Treatment of Otomycosis". Multicenter, randomized, 2-arm parallel-group, double blind, placebo-controlled study in patients suffering from Otomycosis. This study will compare the efficacy and safety of SVT-15652 otic solution to that of Placebo, when administering one vial twice daily during 14 days.
What is the current status of trial NCT03686384?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 217 participants. The study started on 2020-02-27. Estimated completion is 2021-10-25.
What interventions are being tested in trial NCT03686384?
The interventions under investigation include: Placebo (DRUG), SVT-15652 (DRUG).
Who is sponsoring clinical trial NCT03686384?
This trial is sponsored by Salvat, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.